Detection method and kit for CD35 protein of single extracellular vesicle of urine and application
By isolating and detecting CD35 protein in single extracellular vesicles from urine, the problem of diagnosis and prognosis judgment of acute renal injury in sepsis is solved, early diagnosis and risk assessment is achieved, and single extracellular urinary The detection methods and kits of vesicle CD35 protein have fast and accurate identification and prediction capabilities.
Patent Information
- Application Number
- CN202411136280.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-29
AI Technical Summary
Currently, there are no effective markers for early diagnosis and prognosis judgment, making it difficult to accurately diagnose and predict the risk of acute renal injury in sepsis.
By isolating and detecting CD35 protein in single extracellular vesicles from urine, using enzyme-linked immunosorbent assay to determine its expression level, combined with acetylcholinesterase counting, a detection method for CD35 protein in single extracellular vesicles in urine was developed and Kits for diagnosing and assessing the severity and risk of mortality in acute kidney injury in sepsis.
It has achieved early diagnosis and severity assessment of acute renal injury in sepsis, and has the advantages of non-invasiveness, good stability, easy operation and short detection cycle. It can quickly detect the expression level of CD35 protein in single extracellular vesicles in urine, and has excellent and predictive capabilities, including subclinical acute renal injury, risk of death and progression of acute renal disease.
Smart Images

Figure CN119044502A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and discloses a detection method, a kit and an application of a single extracellular vesicle CD35 protein in urine. Background Art
[0002] The incidence of acute kidney injury in sepsis is high, and it has a high mortality rate and a poor prognosis risk. Currently, there are no markers for early diagnosis and prognosis of acute kidney injury in sepsis. Summary of the invention
[0003] To solve the above problems, we analyzed the proteome of a single urine extracellular vesicle and identified that a subpopulation of single extracellular vesicles with CD35 as the main expression protein has a good advantage in diagnosing acute kidney injury in sepsis. The CD35 protein expression level of urine extracellular vesicles captured by enzyme-linked immunosorbent assay was determined, and the extracellular vesicles were counted according to the content of acetylcholinesterase on urine extracellular vesicles to achieve the determination of the CD35 protein expression level of a single urine extracellular vesicle. The results showed that the detection of the expression level of CD35 protein in a single urine extracellular vesicle can realize the diagnosis of acute kidney injury in sepsis and early subclinical acute kidney injury, and is related to the severity of acute kidney injury and the duration of kidney injury, progression to acute kidney disease and the risk of death. Based on this, the present invention proposes a detection method, a kit and an application of CD35 protein in a single urine extracellular vesicle.
[0004] The present invention includes the following technical solutions:
[0005] A method for detecting CD35 protein in a single extracellular vesicle in urine, the method comprising:
[0006] 1) Isolation of extracellular vesicles from urine;
[0007] 2) Detect the total CD35 expression by sandwich ELISA;
[0008] 3) The amount of CD35 expression on a single extracellular vesicle was calculated by detecting the number of extracellular vesicles in the sample.
[0009] Furthermore, in the above-mentioned method for detecting CD35 protein in a single extracellular vesicle in urine, the step of separating the extracellular vesicles in step 1) comprises:
[0010] S1: Urine samples were centrifuged at 3000g and 13500g for 20 min at 4°C to remove cell debris and large extracellular vesicles.
[0011] S2: The small extracellular vesicles were obtained by ultracentrifugation at 200000 g for 2 h, and the extracellular vesicle pellet was suspended in 30 μL of PBS buffer and stored at -80°C.
[0012] Furthermore, in the above-mentioned method for detecting CD35 protein in a single extracellular vesicle in urine, the step of sandwich enzyme-linked immunosorbent assay detection in step 2) comprises:
[0013] S1: Isolation of small extracellular vesicles from urine by binding the extracted extracellular vesicles to pre-coated CD35 antibodies, followed by incubation with biotinylated secondary antibodies and HRP-conjugated streptavidin solutions, followed by labeling with a colorimetric primer.
[0014] S2: The number of extracellular vesicles in the sample was detected using a commercial kit. The protein concentration determined by ELISA was corrected by the number of exosomes and then standardized to obtain the expression level of CD35 in a single extracellular vesicle in urine.
[0015] Furthermore, in the above-mentioned method for detecting single extracellular vesicle CD35 protein in urine, the marker is single extracellular vesicle CD35 protein in urine.
[0016] The present invention also discloses an application of a preparation for determining the content or expression level of a single extracellular vesicle CD35 protein in urine in the preparation of a preparation for early diagnosis or prognosis monitoring of acute kidney injury caused by sepsis, the application comprising:
[0017] Whether the subject suffers from septic acute kidney injury is determined by detecting the expression level of single extracellular vesicle CD35 protein in the subject's urine.
[0018] Furthermore, in the above application, the method for determining whether the subject suffers from septic acute kidney injury comprises:
[0019] The parameters related to the content or expression level of single extracellular vesicle CD35 protein are compared and analyzed with the sample parameters, wherein the sample parameters are selected from the parameters of normal content or expression level of single extracellular vesicle CD35 protein in the previous test sample of the subject and / or the specified urine.
[0020] The present invention also discloses a kit for evaluating whether a patient has acute kidney injury caused by sepsis by measuring the content or expression level of CD35 protein in a single extracellular vesicle of urine.
[0021] The present invention also discloses a kit for determining the degree of acute kidney injury caused by sepsis in a subject by measuring the content or expression level of CD35 protein in a single extracellular vesicle in urine.
[0022] The present invention also discloses an application of a preparation for determining the content or expression level of CD35 protein in a single extracellular vesicle of urine in the preparation of a kit for determining whether a patient has acute kidney injury caused by sepsis, wherein the application comprises:
[0023] Whether the subject suffers from septic acute kidney injury is determined by detecting the protein content or expression level of single extracellular vesicle CD35 in the subject's urine.
[0024] Furthermore, in the above application, the method for judging the degree of acute kidney injury in sepsis in the subject includes: comparing and analyzing the relevant parameters of the content or expression level of the protein of a single extracellular vesicle CD35 in the urine of the subject with the sample parameters; if the relevant parameters are higher than the sample parameter threshold, it is mild acute kidney injury in sepsis, otherwise it is severe acute kidney injury in sepsis; the sample parameters are the specified parameters of the content or expression level of a single extracellular vesicle CD35 protein in urine.
[0025] The present invention has the following beneficial effects:
[0026] The invention discloses a detection method, a kit and application of urine single extracellular vesicle CD35 protein.
[0027] The detection method and application proposed in the present invention have the advantages of being non-invasive, stable, easy to operate and having a short detection cycle, and can be used for the rapid detection of the expression level of CD35 protein in a single extracellular vesicle in urine;
[0028] The kit proposed by the present invention can be used to detect the content or expression level of CD35 protein in a single extracellular vesicle in the urine of a subject, and determine whether the subject suffers from septic acute kidney injury (AUC: 0.89, 95% CI: 0.83-0.95), and has excellent ability to identify patients with early subclinical acute kidney injury (AUC: 0.84, 95% CI: 0.74-0.94);
[0029] The CD35 protein in a single extracellular vesicle in urine proposed in the present invention is used as a marker. Detection of the marker can be used to evaluate the prognosis of acute kidney injury in sepsis, including persistent acute kidney injury (AUC: 0.77, 95% CI: 0.65-0.90), risk of death (AUC: 0.70, 95% CI: 0.54-0.86), and risk of progression to acute kidney disease (AUC: 0.66, 95% CI: 0.53-0.79). BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 . Screening and verification of differential expression of single extracellular vesicle proteins:
[0031] a. The results of proteomic screening of single extracellular vesicles showed that CD35 and CD21 were significantly reduced in the acute kidney injury group; b. Cluster analysis of differentially expressed single extracellular vesicle proteins in sepsis patients; c. Five machine learning algorithms (random forest, support vector machine, XGBOOST, LASSO regression, neural network) jointly identified CD35 and CD21 as the main differentially expressed proteins; d. Single molecule fluorescence staining confirmed that both CD35 and CD21 were localized on extracellular vesicles; e. Western blot identified that the expression level of CD35 protein in single extracellular vesicles after correction of CD9 was significantly reduced in the acute kidney injury group, while CD21 reached statistical significance;
[0032] Figure 2 Reduced CD35 expression levels on individual extracellular vesicles were associated with clinical parameters of acute kidney injury:
[0033] a. Decreased expression of CD35 in single extracellular vesicles is associated with clinical parameters of acute kidney injury: Sample collection and recording process of patients with sepsis; b. The expression level of CD35 protein in single extracellular vesicles is significantly reduced; c. ROC curve analysis shows that CD35 in single extracellular vesicles in urine has discriminatory value for acute kidney injury in sepsis and non-acute kidney injury in sepsis (AUC=0.89, 95%CI, 0.73-0.95); d. The expression of CD35 in single extracellular vesicles gradually decreases with the improvement of acute kidney injury grade; e. The expression of CD35 in single extracellular vesicles is significantly reduced in persistent AKI; f. ROC curve analysis shows that CD35 in single extracellular vesicles in urine has predictive value for persistent acute kidney injury in sepsis (A UC=0.77, 95%CI, 0.65-0.90); g. The results of survival curve analysis showed that the patients with high expression of CD35 in single extracellular vesicles had a lower median recovery time from AKI; hk. The correlation between the expression of CD35 in single extracellular vesicles and glomerular filtration rate (h), serum creatinine (i), procalcitonin (j) and C-reactive protein (k); l. The results of linear regression analysis and smooth curve fitting showed that with the increase of CD35 expression in single extracellular vesicles, the glomerular filtration rate of patients gradually increased; *: p<0.05; **: p<0.01; ***: p<0.001; EV, extracellular vesicle; AKI, acute kidney injury group; eGFR, estimated glomerular filtration rate; Scr, serum creatinine; CRP, C-reactive protein;
[0034] Figure 3 Reduction in CD35 expression levels on individual extracellular vesicles was associated with clinical outcomes in patients:
[0035] a. The expression of single extracellular vesicle CD35 was not associated with the length of ICU stay; b. The expression of single extracellular vesicle CD35 was not associated with the risk of renal replacement therapy; c. The expression level of single extracellular vesicle CD35 in the acute kidney injury death group was significantly reduced, and had a certain predictive effect on the risk of death (AUC: 0.70); d. The median survival time of death in the acute kidney injury group with higher single extracellular vesicle CD35 expression was lower; e. The expression of single extracellular vesicle CD35 was significantly reduced in patients who progressed to acute kidney disease; f. The expression of single extracellular vesicle CD35 was not significantly associated with the progression to chronic kidney disease; RT, renal replacement therapy; AKD, acute kidney injury; CKD, chronic kidney injury;
[0036] Figure 4 CD35 expression levels of single extracellular vesicles can enable early diagnosis of subclinical sepsis-induced acute kidney injury:
[0037] a. Sampling flow chart for patients with subclinical acute kidney injury; b. The expression of single extracellular vesicle CD35 was significantly reduced in subclinical acute kidney injury in sepsis; c. ROC curve analysis results showed that the expression of single extracellular vesicle CD35 could predict the risk of subsequent clinical diagnosis of acute kidney injury; de. The expression of single extracellular vesicle CD35 could predict the risk of subsequent severe acute kidney injury in patients with subclinical acute kidney injury; fg. The expression of single extracellular vesicle CD35 could predict the risk of subsequent persistent acute kidney injury in patients with subclinical acute kidney injury; h. Logistic regression smooth curve fitting showed that as the expression of single extracellular vesicle CD35 increased, the risk of subsequent clinical diagnosis of acute kidney injury in patients decreased; ij. The expression of single extracellular vesicle CD35 was related to the maximum serum creatinine (i) and minimum glomerular filtration rate (j) of patients with subclinical acute kidney injury after admission. DETAILED DESCRIPTION
[0038] A method for detecting CD35 protein in a single extracellular vesicle in urine, the method comprising:
[0039] Small extracellular vesicles are separated from urine, and total protein in the extracellular vesicles is extracted. The expression level of CD35 in the total protein is determined by enzyme-linked immunosorbent assay, and further corrected by the extracellular vesicle count determined by acetylcholinesterase to achieve the expression determination of CD35 at the level of single extracellular vesicles.
[0040] In some embodiments, the step of detecting by enzyme-linked immunosorbent assay comprises:
[0041] Small extracellular vesicles were isolated from urine by combining the extracted extracellular vesicles with pre-coated CD35 antibodies, and then incubated with biotinylated antibodies and HRP-conjugated streptavidin solutions, respectively. The samples were then labeled with a colorimetric primer and detected by an ELISA reader at 450 nm.
[0042] In some embodiments, the step of counting extracellular vesicles comprises:
[0043] Add 50 μL of standard and test sample to each well of a 96-well polystyrene plate, and then add 50 μL each of buffer a and buffer B to make a total reaction volume of 150 μL. The mixture was gently stirred and incubated at room temperature for 20 minutes. Fluorescence was measured using a fluorometer at an excitation wavelength of 570 nm and an emission wavelength of 590 nm.
[0044] In some embodiments, the step of isolating extracellular vesicles comprises: centrifuging the urine sample at 3000 g and 13500 g for 20 min at 4° C. to remove cell debris and large extracellular vesicles;
[0045] The small extracellular vesicles were obtained by ultracentrifugation at 200000 g for 2 h, and the precipitate was suspended in 150 μL of PBS buffer and stored at -80°C.
[0046] The technical scheme in the embodiment of the present invention is clearly and completely described below, and it is obvious that the described embodiment is only a part of the embodiment of the present invention, rather than all embodiments. Based on the embodiment in the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work premise belong to the scope of protection of the present invention. The reagent or instrument used in the embodiment of the present invention do not indicate the manufacturer, and are all conventional reagent products that can be obtained by commercial purchase.
[0047] Example 1
[0048] (1) Isolation and identification of small extracellular vesicles from urine.
[0049] 50 ml of urine was collected from patients with acute kidney injury due to sepsis, patients with non-acute kidney injury due to sepsis, and healthy volunteers, and small extracellular vesicles were separated and purified by differential centrifugation. The specific method was as follows: all separation steps were carried out at 4°C, urine samples were centrifuged at 3000g and 13500g for 20 minutes to remove cell debris and large extracellular vesicles; small extracellular vesicles were obtained by ultracentrifugation at 200000g for 2 hours. The precipitate was suspended in 150 μL PBS buffer and stored at -80°C.
[0050] (2) Identification of small extracellular vesicles in urine
[0051] 1) Electron microscopy observation: The purified exosomes were placed on a nickel grid and stained with 2% phosphotungstic acid for 5 minutes. The morphology and size of the exosomes were observed using a HT7700 (Hitachi, Japan) transmission electron microscope at 80 kV.
[0052] 2) Particle size analysis was performed using a ZetaView PMX 110 nanoparticle tracking analyzer (Particle Metrix, Meerbusch, Germany).
[0053] 3) Western blot analysis: After the exosome protein was lysed, it was added to a 10% polyacrylamide gel and transferred to a PVDF membrane after electrophoresis. Mouse anti-Alix antibody (Santa Cruz, sc-53540), mouse anti-CD63 antibody (Abcam, ab213090), and rabbit anti-CD81 antibody (CST, 10037) were diluted at a ratio of 1:1000 and incubated overnight. After incubation with HRP-labeled secondary antibody, luminescence detection was performed using chemiluminescence detection reagent (ECL).
[0054] (3) Protein extraction and ELISA
[0055] 50ul of the extracted small extracellular vesicles were selected and mixed with RIPA lysis buffer at a ratio of 1:1, 100X protease inhibitors were added, and lysis was performed on ice for 2 hours. Centrifuge at 13500g for 15 minutes and take the protein supernatant. The enzyme-linked immunosorbent assay standards and samples were added to a 96-well plate pre-coated with CD35 binding antibodies and incubated at room temperature for 3 hours. Wash three times with PBST and dry thoroughly with a paper towel after the last wash. 100μL of the prepared biotinylated antibody was added to each well and incubated at room temperature for 1 hour. This washing step was repeated three times. Then 100μL of the prepared streptavidin solution was added and incubated at room temperature for 45 minutes. After three washes, 100μL of TMB color substrate was added, incubated at room temperature for 30 minutes, stop solution was added, and the absorbance was immediately measured at 450nm using a spectrophotometer and the concentration was calculated.
[0056] (4) Urine extracellular vesicle count
[0057] Add 50 μL of standard and test sample to each well of a 96-well polystyrene plate, and then add 50 μL each of buffer a and buffer B to make a total reaction volume of 150 μL. The mixture was gently stirred and incubated at room temperature for 20 minutes. Fluorescence was measured using a fluorometer at an excitation wavelength of 570 nm and an emission wavelength of 590 nm.
[0058] Example 2
[0059] Differential expression screening and validation of single extracellular vesicle proteins.
[0060] The limma package was used to perform differential proteomic analysis of single extracellular vesicles in 8 patients with acute kidney injury due to sepsis and 8 patients with non-acute kidney injury due to sepsis. CD35 and CD21 were identified as the main differential proteins, and sepsis patients with acute kidney injury and non-acute kidney injury could be distinguished ( Figure 1 ac). Single-molecule fluorescence staining was then used to confirm that CD35 and CD21 co-localized with extracellular vesicles ( Figure 1 d). Western blot analysis revealed that the expression of CD35 in single extracellular vesicles was significantly downregulated after CD9 correction, while CD21 showed no significant change ( Figure 1 e).
[0061] Example 3
[0062] Reduced CD35 expression levels on individual extracellular vesicles were associated with clinical parameters of acute kidney injury.
[0063] By comparing the urine of 70 patients with acute kidney injury and 44 patients with sepsis without acute kidney injury, it was found that the CD35 expression of single extracellular vesicles was significantly reduced, and had excellent ability to distinguish patients with acute kidney injury (AUC: 0.89, 95% CI: 0.83-0.95) ( Figure 2 ac). In addition, CD35 expression of single extracellular vesicles can predict the risk of severe acute kidney injury and persistent acute kidney injury (AUC: 0.77, 95% CI: 0.65-0.90) ( Figure 2 ef) and was associated with median recovery time from acute kidney injury ( Figure 2 g), which suggests that the CD35 expression of a single extracellular vesicle can well predict the patient's short-term adverse risk. Through correlation analysis with important clinical parameters of acute kidney injury, the results showed that the CD35 expression of a single extracellular vesicle was significantly correlated with the maximum serum creatinine, minimum glomerular filtration rate, procalcitonin, and C-reactive protein of patients with acute kidney injury due to sepsis after admission ( Figure 2 hk), suggesting that the expression of CD35 on a single extracellular vesicle can reflect the severity of acute kidney injury in sepsis. In order to exclude the influence of confounding factors, after correcting for gender, age, cardiovascular disease, and smoking history using linear regression analysis, it was still found that the CD35 on a single extracellular vesicle was significantly correlated with the lowest glomerular filtration rate of patients subsequently admitted to the hospital, suggesting that the expression of CD35 on a single extracellular vesicle affects the key predictor of the patient's subsequent glomerular filtration rate ( Figure 2 l).
[0064] Example 4
[0065] Reduced CD35 expression levels on individual extracellular vesicles are associated with clinical outcomes in patients
[0066] A follow-up analysis was performed on 70 patients with acute kidney injury caused by sepsis to observe whether the expression of CD35 in single extracellular vesicles was associated with the subsequent adverse outcomes of patients. Correlation analysis found that the expression level of CD35 in single extracellular vesicles was significantly correlated with the length of hospital stay of patients with acute kidney injury ( Figure 3 a) Whether renal replacement therapy is needed ( Figure 3 b) was not related to the risk of death (AUC: 0.70, 95% CI: 0.54-0.86) and the risk of progression to acute kidney disease (AUC: 0.66, 95% CI: 0.53-0.79). Figure 3 ce). No predictive effect on progression to chronic kidney disease ( Figure 3 f)
[0067] Example 5
[0068] CD35 expression levels of single extracellular vesicles can enable early diagnosis of subclinical sepsis-induced acute kidney injury
[0069] The urine of patients with sepsis but not acute kidney injury (n=72) was collected and purified, and the expression of CD35 in single extracellular vesicles was measured ( Figure 4 a) It was found that the expression of CD35 on single extracellular vesicles could enable the identification of patients with subclinical acute kidney injury (AUC: 0.84, 95% CI: 0.74-0.94) ( Figure 4 b) and had a certain predictive value for subsequent severe acute kidney injury (AUC: 0.69, 95% CI: 0.49-0.89) ( Figure 4 de) and risk of persistent renal injury (AUC: 0.72, 95% CI: 0.52-0.92) ( Figure 4 fg). The results of logistic regression fitting and smooth curve visualization showed that the expression of CD35 on single extracellular vesicles was an independent predictor of subsequent clinical diagnosis of acute kidney injury ( Figure 4 h). Correlation analysis results showed that the expression of CD35 in single extracellular vesicles was significantly correlated with the minimum glomerular filtration rate (GFR) of patients with subclinical acute kidney injury after admission. Figure 4 i) and maximum serum creatinine ( Figure 4 j)
[0070] According to the above examples, it can be concluded that the expression level of CD35 protein in a single extracellular vesicle in urine has a certain reference value for the judgment of acute kidney injury caused by sepsis. Therefore, the present invention proposes the above kit and application to achieve the purpose of quickly detecting the expression level of CD35 protein in a single extracellular vesicle in urine caused by acute kidney injury caused by sepsis.
[0071] The above embodiments show and describe the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the above embodiments do not limit the present invention in any form, and any technical solution obtained by equivalent replacement or equivalent transformation falls within the protection scope of the present invention.
Claims
1. A method for detecting CD35 protein in a single extracellular vesicle in urine, characterized in that: The method comprises: 1) Isolation of extracellular vesicles from urine; 2) Detect the total CD35 expression by sandwich ELISA; 3) The amount of CD35 expression on a single extracellular vesicle was calculated by detecting the number of extracellular vesicles in the sample.
2. The method for detecting CD35 protein in a single extracellular vesicle in urine according to claim 1, characterized in that: The step of isolating extracellular vesicles in step 1) comprises: S1: Urine samples were centrifuged at 3000g and 13500g for 20 min at 4°C to remove cell debris and large extracellular vesicles. S2: The small extracellular vesicles were obtained by ultracentrifugation at 200000 g for 2 h, and the extracellular vesicle pellet was suspended in 30 μL of PBS buffer and stored at -80°C.
3. The method for detecting CD35 protein in a single extracellular vesicle in urine according to claim 1, characterized in that: The step of sandwich ELISA detection in step 2) comprises: S1: Isolation of small extracellular vesicles from urine by combining the extracted extracellular vesicles with pre-coated CD35 antibodies, followed by incubation with biotinylated secondary antibodies and HRP-conjugated streptavidin solutions, followed by labeling the samples with a colorimetric primer and detection with a microplate reader at 450 nm. S2: The number of extracellular vesicles in the sample was detected using a commercial kit. The protein concentration determined by ELISA was corrected by the number of exosomes and then standardized to obtain the expression level of CD35 in a single extracellular vesicle in urine.
4. A marker for detecting acute kidney injury in sepsis, characterized in that: The marker is urine single extracellular vesicle CD35 protein.
5. Use of a preparation for determining the content or expression level of CD35 protein in a single extracellular vesicle of urine in the preparation of a preparation for early diagnosis or prognosis monitoring of acute kidney injury caused by sepsis, characterized in that: The applications include: Whether the subject suffers from septic acute kidney injury and subclinical acute kidney injury is determined by detecting the expression level of single extracellular vesicle CD35 protein in the subject's urine.
6. The use according to claim 5, characterized in that: The method for determining whether a subject suffers from septic acute kidney injury and subclinical acute kidney injury comprises: The parameters related to the content or expression level of single extracellular vesicle CD35 protein are compared and analyzed with the sample parameters, wherein the sample parameters are selected from the parameters of normal content or expression level of single extracellular vesicle CD35 protein in the previous test sample of the subject and / or the specified urine.
7. A kit for diagnosing acute kidney injury caused by sepsis by measuring the content or expression level of CD35 protein in single extracellular vesicles in urine.
8. A kit for determining the degree of acute kidney injury caused by sepsis in a subject by measuring the content or expression level of CD35 protein in a single extracellular vesicle in urine.
9. Use of a preparation for determining the content or expression level of CD35 protein in a single extracellular vesicle of urine in the preparation of a kit for determining the degree of acute kidney injury in sepsis, characterized in that: The applications include: The stage and degree of septic acute kidney injury in the subject can be determined by detecting the protein content or expression level of single extracellular vesicle CD35 in the subject's urine.
10. The use according to claim 9, characterized in that: The method for determining whether a subject suffers from septic acute kidney injury comprises: comparing and analyzing the relevant parameters of the content or expression level of a single extracellular vesicle CD35 protein in the subject's urine with a sample parameter; if the relevant parameter is higher than the sample parameter threshold, the septic acute kidney injury is mild; if the parameter is lower than the sample parameter threshold, the subject suffers from severe acute kidney injury; the sample parameter is a specified parameter of the content or expression level of a single extracellular vesicle CD35 protein in urine.
11. Use of a preparation for determining the content or expression level of CD35 protein in a single extracellular vesicle of urine in the preparation of a kit for evaluating the prognosis of patients with acute kidney injury caused by sepsis, characterized in that: The applications include: The risk of subsequent progression to persistent acute kidney injury, acute kidney disease and subsequent death in patients is assessed by detecting the content or expression level of single extracellular vesicle CD35 protein in the subject's urine.
Citation Information
Cited By
Detection method for CD35 protein in individual extracellular vesicles of urine, kit and use thereof
WO2026041152A1
